John Reynders

With over 25 years of leadership experience in life sciences, data-sciences, and technology in organizations spanning early-stage biotechs, multi-national pharmaceuticals, and a top U.S national research laboratory, John Reynders established Reynders Consulting in 2020. Reynders Consulting is uniquely positioned to help companies innovate at the intersection of the life sciences and data sciences. Prior to starting Reynders Consulting, John led Alexion’s Data Sciences, Genomics, and Bioinformatics (DGB) organization in the design, building, and deployment of DGB solutions spanning R&D, Commercial, Strategy, and Business Development. John delivered key capabilities for Alexion including a novel graph-database of the entire rare-disease landscape annotated with prevalence, severity, competitive intensity, and genetic signature; a genomics-based rare-disease patient prevalence platform to inform licensing/acquisition opportunities; AI-based phenotype- and genome-driven rare-disease diagnosis decision-support systems; genomic-based analyses in support of clinical trial design; partnerships with commercial leaders to provide genomic and data-sciences insight in support of launch strategies; key opinion leader engagements in core therapeutic areas; and pathway/network analysis techniques to inform target selection across multiple discovery programs. John has received many industry recognitions including 2 BioIT Judge’s awards, a Rare Genes Champion of Hope award, publication in Science: Translational Medicine, part of the GUINNESS Book of World Records effort for fastest genetics-based diagnosis, and recognition by the National Human Genome Research Institute as a top 10 most significant advance for genomic medicine in 2019. John has a MBA from Northwestern University – Kellogg School of Management, a PhD in Applied and Computational Mathematics from Princeton University, and a Bachelor of Science degree in Mathematics from Rensselaer Polytechnic Institute.